Health Tech Capitol | Promega, BioIVT Partner
16860
post-template-default,single,single-post,postid-16860,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Promega, BioIVT Partner

29 May Promega, BioIVT Partner

Posted at 10:24h in Uncategorized by
0 Likes

Promega has partnered with BioIVT, a provider of research models and services for drug and diagnostic development, the company announced today.

According to a release, BioIVT will offer Promega Immune Checkpoint and antibody-dependent cell-mediated cytotoxicity (ADCC) Reporter Bioassays to support immunology and immuno-oncology research.

“We are excited to team up with BioIVT to help advance immunology and immuno-oncology research,” Promega Vice President of Life Sciences Thomas Livelli said in a statement. “BioIVT shares our commitment to high-quality data and excellent customer service, and it has also demonstrated the ability to create new, cutting-edge assays.”

Read more at Madison Startups

No Comments

Sorry, the comment form is closed at this time.